Synergistic Antimicrobial Prophylaxis Systems

The present invention relates to novel synergistic combinations of peptides derived from Acinetobacter baumannii with distinct technologies such as AI, IoT, blockchain, and new materials to create more powerful systems for personalized antimicrobial prophylaxis and therapy.

The original patent disclosed peptides derived from Acinetobacter baumannii for vaccination, but it had limitations in terms of personalized approaches, real-time monitoring, and tracking efficacy. The new inventive concept addresses these limitations by integrating the patented peptides with other distinct technologies to create more effective and personalized systems.

The synergistic combinations disclosed herein integrate the peptides derived from Acinetobacter baumannii with AI-powered diagnostic modules for identifying specific microbial strains, IoT-enabled sensors for real-time monitoring of immune responses, blockchain-based tracking systems for monitoring vaccination efficacy, and novel materials such as graphene-based adjuvants and nanotechnology-enabled delivery systems. These combinations enable personalized antimicrobial prophylaxis and therapy, real-time monitoring, and tracking of vaccination efficacy.

The new claims are novel and non-obvious as they combine the peptides derived from Acinetobacter baumannii with distinct technologies to create synergistic systems that are more effective and personalized than the original patent. The integration of these technologies provides a new and inventive approach to antimicrobial prophylaxis and therapy.

Alternative embodiments of the inventive concept include the use of different AI algorithms, IoT sensors, blockchain platforms, and novel materials. Variations of the inventive concept could include the integration of additional technologies such as machine learning, genomics analysis, and biometrics.

The inventive concept has significant commercial potential in the fields of antimicrobial prophylaxis and therapy, personalized medicine, and digital health. The target market includes pharmaceutical companies, biotech companies, and healthcare providers.